Avidity Biosciences
143 hedge funds and large institutions have $915M invested in Avidity Biosciences in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 64 increasing their positions, 32 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
22% less capital invested
Capital invested by funds: $1.17B → $915M (-$251M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
64% less call options, than puts
Call options by funds: $244K | Put options by funds: $674K
Holders
143
Holding in Top 10
2
Calls
$244K
Puts
$674K
Top Buyers
| 1 | +$57.7M | |
| 2 | +$20.1M | |
| 3 | +$15.2M | |
| 4 |
CAC
Cowen and Company
New York
|
+$11.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.32M |
Top Sellers
| 1 | -$36.3M | |
| 2 | -$19.4M | |
| 3 | -$9.07M | |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$7.67M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$6.11M |